Martin H.
- Country
- Denmark
- Department
- Hematology
Research Overview
- Phase 1 Study of JNJ-80948543, a T-cell Redirecting Antibody, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
- Evaluation of Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 with Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Patients
- Safety Evaluation of SGN-35C in Adult Patients with Advanced Diffuse Large B-Cell Lymphoma, Hodgkin Disease, Peripheral T-Cell Lymphoma, and Anaplastic Large-Cell Lymphoma
Data & Insights
Has run more than one trial at 113 of 228 partner sites.
Specializations
Lymphoma Research
Specializes in investigating novel therapeutic approaches for B-cell lymphomas and Hodgkin lymphoma, with particular emphasis on advanced and refractory cases.
- Advanced stage Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma
- Mantle Cell Lymphoma
Focuses on response-adapted treatment strategies and early intervention protocols in lymphoid malignancies.
Innovative Therapies
Leads research into targeted immunotherapy and combination treatment approaches for hematologic malignancies.
- T-cell Redirecting Antibodies
- Novel Therapeutic Combinations
- PET-Response Adapted Treatments
Evaluates emerging biologic agents and their integration with established treatment regimens.
Treatment Resistance
Investigates therapeutic solutions for relapsed/refractory disease in various lymphoma subtypes.
- Refractory B-Cell Lymphomas
- Chronic Lymphocytic Leukemia
- Advanced B-Cell Malignancies
Develops strategies to overcome treatment resistance in aggressive lymphomas.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.